Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2007 on NSE
Last close ₹847.30up ₹10.85 (1.30%)BSE ₹846.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹836.45.
2 Nov: open ₹839.20, high ₹861.15, low ₹821.00
52-week range of traded prices to 2 Nov 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,074 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,09,48449.1% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 13 of 18.
Dec 2012
3 Dec · Change in Company Secretary
Mrs. Bhoomijha Murali, Sr. General Manager- Legal & Company Secretary has resigned, and relieved from the services of the Company with effect from the closing hours of November 30, 2012. Mr. L Chandrasekar, Executive Vice President - Finance & Secretary has taken over as the Company Secretary from December 01, 2012. Mr. L Chandrasekar, will also be the Compliance Officer of the Company.
Nov 2012
27 Nov · Management
Shri Bharat D Shah and Shri Deepak Vaidya, Directors have resigned from the Board of the Company with effect from November 15, 2012 and November 19, 2012 respectively.
Oct 2012
26 Oct · Board meeting
Inter alia to consider and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2012.9 Oct · Meeting
Sep 2012
21 Sep · Disclosure of Voting Pattern - Clause 35A
Aug 2012
14 Aug · Results
6 Aug · Board meeting
Inter-alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2012.
Jul 2012
Jun 2012
8 Jun · Updates
Industrial Development Bank of India has withdrawn the nomination of Shri. T. A. Ganesh and instead appointed Shri. K. Biju George, Deputy General Manager, IDBI Bank Ltd, Chennai as its nominee on the Board of the Company with effect from June 06, 2012.
May 2012
18 May · Business
Allotment Committee of the Board of Directors has allotted 10,000 equity shares of Rs.10 each upon exercise of vested options by one of the employees under ESOP-2010 scheme on May 17, 2012.14 May · Dividend
Board of Directors of the Company at its meeting held on May 14, 2012 has recommended a dividend of Rs. 3/- per share on the equity share of Rs.10/- each. Further, the dividend on Equity shares, will be paid subject to the approval of shareholders in the ensuing Annual General Meeting, and the same will be paid / dispatched during 2nd week of August 2012.4 May · Board meeting
To :- (1) Approve the audited financial results of the Company for the financial year ended March 31, 2012; (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2012.
Apr 2012
3 Apr · Updates
Hon'ble High Court of Madras has sanctioned the Scheme of Amalgamation for Merger of Orchid Research Laboratories Limited with Orchid Chemicals & Pharmaceuticals Limited.
Mar 2012
Feb 2012
8 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 46380.79 lacs for quarter ending on 31-DEC-2011 against Rs. 42714.76 lacs for the quarter ending on 31-DEC-2010. Net Profit / (Loss) of Rs. (1012.47) lacs for the quarter ending on 31-DEC-2011 against Rs. 5256.61 lacs for the quarter ending on 31-DEC-2010.
Jan 2012
25 Jan · Board meeting
To take on record the unaudited financial results of orchid for the period from October 01, 2011 to December 31, 2011.20 Jan · Updates
Shri R. Sankaran has resigned from the Board of the Company with effect from January 09, 2012.7 Jan · Board meeting
Board of Directors of the Company at their meeting held on January 07, 2012, inter-alia has approved a Scheme of Amalgamation ('the Scheme') for merger of company's wholly owned subsidiary viz. Orchid Research Laboratories Limited ('the transferor company') with Orchid under the provisions of Sections 391 to 394 of the Companies Act, 1956. The Appointed date of the Amalgamation is April 01, 2010 and the Scheme is subject to the approval of The Hon'ble High Court of Madras. The transferor company being a wholly owned subsidiary no fresh shares will be issued by the Company upon the Scheme coming into effect.
Dec 2011
28 Dec · Board meeting
To consider the proposal for merger of its wholly owned subsidiary, Orchid Research Laboratories Ltd with Orchid Chemicals & Pharmaceuticals Ltd.14 Dec · Meeting
9 Dec · Meeting
Shareholders of the Company by way of postal ballot have approved on December 08, 2011, with requisite majority, the repricing of 8,64,500 options granted to employees on October 28, 2010 under Orchid ESOP 2010 Scheme, from Rs.329.55 to Rs.166.15 per share.
Nov 2011